Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47,433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team. Smith PF, et al. Among authors: wu h. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61. doi: 10.1128/AAC.49.8.3558-3561.2005. Antimicrob Agents Chemother. 2005. PMID: 16048984 Free PMC article. Clinical Trial.
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD; Adult AIDS Clinical Trials Group Protocol 368/886 Study Team. DiCenzo R, et al. Among authors: wu h. Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35. doi: 10.1128/AAC.47.6.1929-1935.2003. Antimicrob Agents Chemother. 2003. PMID: 12760869 Free PMC article. Clinical Trial.
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
Eron JJ Jr, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD; ACTG5126 Study Team. Eron JJ Jr, et al. Among authors: wu h. Antimicrob Agents Chemother. 2009 Jun;53(6):2335-41. doi: 10.1128/AAC.01387-08. Epub 2009 Mar 23. Antimicrob Agents Chemother. 2009. PMID: 19307363 Free PMC article. Clinical Trial.
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JG; Adult AIDS Clinical Trials Group 5055 Protocol Team. Acosta EP, et al. Among authors: wu h. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1358-66. doi: 10.1097/00126334-200411010-00004. J Acquir Immune Defic Syndr. 2004. PMID: 15483465 Clinical Trial.
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.
Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM. Wu H, et al. J Infect Dis. 1999 Apr;179(4):799-807. doi: 10.1086/314670. J Infect Dis. 1999. PMID: 10068574
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Kuritzkes DR, et al. Among authors: wu h. J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244. J Infect Dis. 2000. PMID: 10669331 Clinical Trial.
47,433 results
You have reached the last available page of results. Please see the User Guide for more information.